breast cancer stem cells

[Journal of Medicinal Chemistry] A natural product 5α-epoxyalantolactone (5α-EAL) was discovered as an anti-breast cancer stem cells lead compound 5α-EAL was found to be able to notably suppress the function of ANXA2 by covalently targeting cysteine 9 of ANXA2.

[Nature Communications] Scientists described a novel multi-kinase inhibitor, 108600, that suppressed growth, colony and mammosphere forming capacity of breast cancer stem cell-like cells and induced G2M arrest and apoptosis of TNBC cells.

[Oncogene] Macrophages co-cultured with breast cancer cells showed a significant increase in CCL2 expression and promoted β-Catenin-induced breast cancer stem cells (BCSCs) properties, whereas depletion of CCL2 by adding neutralizing antibodies suppressed BSCSs properties.

[British Journal of Cancer] Scientists identified the consistent transcriptome of primary breast cancer stem cells (BCSCs) shared across breast cancer subtypes, and examined the clinical relevance of ITGA7, one of the genes differentially expressed in BCSCs.

[Cell Death Discovery] The roles of small extracellular vesicles (sEVs) from cancer-associated fibroblasts on breast cancer stem cell properties are largely unraveled. Investigators explored the roles of sEVs from cancer-associated fibroblasts on breast cancer progression.

[Communications Biology] Scientists indicated that CSCs may enjoy blood perfusion to maintain their stemness features. Targeting the lysophosphatidic acid/protein kinase D -CD36 signaling pathway may have therapeutic potential to curb tumor progression by disrupting the arteriolar niche and effectively eliminating CSCs.